Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells

Molecular Cancer

Volumn 6, Issue , 2007, Pages

  Wergeland, Line ^a   Sjøholt, Gry ^a   Haaland, Ingvild ^a   Hovland, Randi ^a,b   Bruserud, Øystein ^a,b   Gjertsen, Bjørn Tore ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; DAUNORUBICIN; DNA; MESSENGER RNA; PROTEIN MCL 1; PROTEIN MDM2; FLT3 PROTEIN, HUMAN; MCL1 PROTEIN; MDM2 PROTEIN, HUMAN; PROTEIN BCL 2; PROTEIN P53; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CASE REPORT; CELL STRAIN HL 60; DNA DAMAGE; DOWN REGULATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IONIZING RADIATION; LEUKEMIA CELL; MALE; RADIATION EXPOSURE; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WILD TYPE; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; APOPTOSIS; DAUNORUBICIN; DNA DAMAGE; FEMALE; FMS-LIKE TYROSINE KINASE 3; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RADIATION, IONIZING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34249780126     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-6-33     Document Type: Article

References (43)

1. Smith M Barnett M Bassan R Gatta G Tondini C Kern W Adult acute myeloid leukaemia Crit Rev Oncol Hematol 2004 50 3 197-222 15182826
2. Wheatley K Burnett AK Goldstone AH Gray RG Hann IM Harrison CJ Rees JK Stevens RF Walker H A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties Br J Haematol 1999 107 1 69-79 10.1046/j.1365-2141.1999.01684.x 10520026
3. Anensen N Oyan AM Bourdon JC Kalland KH Bruserud O Gjertsen BT A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia Clin Cancer Res 2006 12 13 3985-3992 10.1158/1078-0432.CCR-05-1970 16818696
4. Myers CE Chabner BA Antracyclines Cancer chemotherapy: Principles and practice Philadelphia, Pa, JB Lippincott Chabner BA, Collins JM 1990 356-381
5. Bose R Verheij M Haimovitz-Friedman A Scotto K Fuks Z Kolesnick R Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals Cell 1995 82 3 405-414 10.1016/0092-8674(95)90429-8 7634330
6. Dimanche-Boitrel MT Meurette O Rebillard A Lacour S Role of early plasma membrane events in chemotherapy-induced cell death Drug Resistance Updates 2005 8 1-2 5-14 10.1016/j.drup.2005.02.003 15939338
7. Laurent G Jaffrezou JP Signaling pathways activated by daunorubicin Blood 2001 98 4 913-924 10.1182/blood.V98.4.913 11493433
8. Hegenbart U Niederwieser D Sandmaier BM Maris MB Shizuru JA Greinix H Cordonnier C Rio B Gratwohl A Lange T Al-Ali H Storer B Maloney D McSweeney P Chauncey T Agura E Bruno B Maziarz RT Petersen F Storb R Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors J Clin Oncol 2006 24 3 444-453 10.1200/ JCO.2005.03.1765 16344316
9. Pagel JM Appelbaum FR Eary JF Rajendran J Fisher DR Gooley T Ruffner K Nemecek E Sickle E Durack L Carreras J Horowitz MM Press OW Gopal AK Martin PJ Bernstein ID Matthews DC 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission Blood 2006 107 5 2184-2191 10.1182/blood-2005-06-2317 16254140
10. Lewanski CR Gullick WJ Radiotherapy and cellular signalling The Lancet Oncology 2001 2 6 366-370 10.1016/S1470-2045(00)00391-0 11905753
11. Bruserud O Ulvestad E Effects of gamma-irradiation on acute myelogenous leukemia blasts: In vitro studies of proliferation, constitutive cytokine secretion, and accessory cell function during T cell activation J Hematother Stem Cell Res 1999 8 4 431-441 10.1089/152581699320199 10634181
12. Stirewalt DL Radich JP The role of FLT3 in haematopoietic malignancies Nat Rev Cancer 2003 3 9 650-665 10.1038/nrc1169 12951584
13. Seedhouse CH Hunter HM Lloyd-Lewis B Massip AM Pallis M Carter GI Grundy M Shang S Russell NH DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412 Leukemia 2006 20 12 2130-2136 10.1038/sj.leu.2404439 17066094
14. Irish JM Anensen N Hovland R Skavland J Borresen-Dale AL Bruserud O Nolan GP Gjertsen BT Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood 2007 109 6 2589-96 10.1182/ blood-2006-02-004234 17105820
15. Kaufmann SH Karp JE Svingen PA Krajewski S Burke PJ Gore SD Reed JC Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse Blood 1998 91 3 991-1000 9446661
16. van Delft MF Wei AH Mason KD Vandenberg CJ Chen L Czabotar PE Willis SN Scott CL Day CL Cory S Adams JM Roberts AW Huang DCS The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized Cancer Cell 2006 10 5 389-399 10.1016/j.ccr.2006.08.027 17097561
17. Fenaux P Preudhomme C Quiquandon I Jonveaux P Lai JL Vanrumbeke M Loucheux-Lefebvre MH Bauters F Berger R Kerckaert JP Mutations of the P53 gene in acute myeloid leukaemia Br J Haematol 1992 80 2 178-183 1550773
18. Schottelius A Brennscheidt U Ludwig WD Mertelsmann RH Herrmann F Lubbert M Mechanisms of p53 alteration in acute leukemias Leukemia 1994 8 10 1673-1681 7523798
19. Bueso-Ramos CE Yang Y deLeon E McCown P Stass SA Albitar M The human MDM-2 oncogene is overexpressed in leukemias Blood 1993 82 9 2617-2623 8219216
20. Stommel JM Wahl GM Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation Embo J 2004 23 7 1547-1556 391059 15029243 10.1038/sj.emboj.7600145
21. Zhang Z Zhang R p53-independent activities of MDM2 and their relevance to cancer therapy Curr Cancer Drug Targets 2005 5 1 9-20 10.2174/ 1568009053332618 15720185
22. Fleckenstein DS Uphoff CC Drexler HG Quentmeier H Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines Leuk Res 2002 26 2 207-214 10.1016/S0145-2126(01)00107-2 11755471
23. Song X Sheppard HM Norman AW Liu X Mitogen-activated protein kinase is involved in the degradation of p53 protein in the bryostatin-1-induced differentiation of the acute promyelocytic leukemia NB4 cell line J Biol Chem 1999 274 3 1677-1682 10.1074/jbc.274.3.1677 9880547
24. Quentmeier H Reinhardt J Zaborski M Drexler HG FLT3 mutations in acute myeloid leukemia cell lines Leukemia 2003 17 1 120-124 10.1038/ sj.leu.2402740 12529668
25. Girnita L Girnita A Larsson O Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor Proc Natl Acad Sci U S A 2003 100 14 8247-8252 166214 12821780 10.1073/pnas.1431613100
26. Komeno Y Kurokawa M Imai Y Takeshita M Matsumura T Kubo K Yoshino T Nishiyama U Kuwaki T Osawa T Ogawa S Chiba S Miwa A Hirai H Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase Leukemia 2005 19 6 930-935 10.1038/sj.leu.2403736 15815726
27. Fang S Jensen JP Ludwig RL Vousden KH Weissman AM Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53 J Biol Chem 2000 275 12 8945-8951 10.1074/jbc.275.12.8945 10722742
28. Linares LK Hengstermann A Ciechanover A Muller S Scheffner M HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53 Proc Natl Acad Sci U S A 2003 100 21 12009-12014 218704 14507994 10.1073/ pnas.2030930100
29. Cheng TH Cohen SN Human MDM2 isoforms translated differentially on constitutive versus p53-regulated transcripts have distinct functions in the p53/MDM2 and TSG101/MDM2 feedback control loops Mol Cell Biol 2007 27 1 111-119 1800643 17060450 10.1128/MCB.00235-06
30. Linares LK Kiernan R Triboulet R Chable-Bessia C Latreille D Cuvier O Lacroix M Le Cam L Coux O Benkirane M Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2 Nat Cell Biol 2007 9 3 331-338 10.1038/ncb1545 17293853
31. Kim KU Xiao J Ni HT Cho KH Spellman SR Low WC Hall WA Changes in expression of transferrin, insulin-like growth factor 1, and interleukin 4 receptors after irradiation of cells of primary malignant brain tumor cell lines Radiat Res 2003 160 2 224-231 10.1667/RR3040 12859234
32. Schmidt-Ullrich RK Valerie KC Chan W McWilliams D Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures Int J Radiat Oncol Biol Phys 1994 29 4 813-819 8040028
33. Gjertsen BT Cressey LI Ruchaud S Houge G Lanotte M Doskeland SO Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line J Cell Sci 1994 107 (Pt 12) 3363-3377 7706392
34. Wiederschain D Kawai H Shilatifard A Yuan ZM Multiple Mixed Lineage Leukemia (MLL) Fusion Proteins Suppress p53-mediated Response to DNA Damage J Biol Chem 2005 280 26 24315-24321 10.1074/jbc.M412237200 15851483
35. Mosselman S Claesson-Welsh L Kamphuis JS van Zoelen EJ Developmentally regulated expression of two novel platelet-derived growth factor alpha-receptor transcripts in human teratocarcinoma cells Cancer Res 1994 54 1 220-225 8261442
36. Chen LL Sabripour M Wu EF Prieto VG Fuller GN Frazier ML A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors Oncogene 2005 24 26 4271-4280 10.1038/sj.onc.1208587 15824741
37. Nijhawan D Fang M Traer E Zhong Q Gao W Du F Wang X Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation Genes Dev 2003 17 12 1475-1486 196078 12783855 10.1101/ gad.1093903
38. Baer MR Sabur KL O'Loughlin KL Starostik P Minderman H The FLT3 Inhibitor PKC412 Interacts Synergistically with Both Daunorubicin and Cytarabine in Acute Myeloid Leukemia (AML) Cells by Heterogeneous Mechanisms ASH Annual Meeting Abstracts 2006 108 11 1378
39. Stone RM Fischer T Paquette R Schiller G Schiffer CA Ehninger G Cortes J Kantarjian H DeAngelo DA Massimini G Li X Phillips P Giles F Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Adult Patients (pts) with Acute Myeloid Leukemia (AML) under Age 61 ASH Annual Meeting Abstracts 2006 108 11 157
40. Bruserud O Effect of dipyridamole, theophyllamine and verapamil on spontaneous in vitro proliferation of myelogenous leukaemia cells Acta Oncol 1992 31 1 53-58 1586506
41. Bruserud O Gjertsen BT von Volkman HL In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: Studies of native AML blasts and AML cell lines J Hematother Stem Cell Res 2000 9 6 923-932 10.1089/152581600750062372 11177606
42. Lanotte M Martin-Thouvenin V Najman S Balerini P Valensi F Berger R NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3) Blood 1991 77 5 1080-1086 1995093
43. Olivier M Eeles R Hollstein M Khan MA Harris CC Hainaut P The IARC TP53 database: New online mutation analysis and recommendations to users Hum Mutat 2002 19 6 607-614 10.1002/humu.10081 12007217